Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus METHYLTESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus METHYLTESTOSTERONE.
HALOTESTIN vs METHYLTESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Category C
Category D/X
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."